Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL

S. Gudowius, K. Recker, H. J. Laws, U. Dirksen, A. Tröger, U. Wieczorek, S. Furlan, U. Göbel, Helmut Hanenberg

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Contemporary risk adapted treatment protocols for childhood acute lymphoblastic leukemia (ALL) rely on accurate risk assessment strategies for disease reoccurrence by incorporating clinical parameters as well as immunological, molecular and cytogenetic features of the blasts at initial manifestation. Additional risk stratification is provided by analysis of the in vitro and in vivo response of the blasts towards standard chemotherapy. Despite adapted therapies, a number of children with good and bad prognostic factors still fail therapy. One approach to this problem might be to incorporate monoclonal antibodies (MoAbs) as additional modalities into the first or second line treatment. Patients and Methods: In order to identify target antigen structures, we analyzed the immunological expression profiles of blasts from 181 patients with B-cell precursor ALL treated at our institution in 11 years according to the CoALL-92/ 97/03 protocols. Blasts were classified according to the EGIL guidelines as 9 proB-, 110 common (c-) and 62 preB-ALL Results: >99 and 96% of patients expressed CD19 and CD22 on >90% of their blasts, respectively. HLA-DR on >95% blasts was present in all patients. CD10 was expressed on all c-/preB-ALL and absent on proB-ALL cells. CD20 was expressed on 11-37% of B-cell precursor ALL samples. CD34 positive blasts were found in 89, 83 and 68% of patients with proB-, c- and preB-ALL, respectively. CD37 expression was detected in 0-18% of patients.

Original languageEnglish (US)
Pages (from-to)327-333
Number of pages7
JournalKlinische Padiatrie
Volume218
Issue number6
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

B-Lymphoid Precursor Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunotherapy
Antigens
Antibodies
HLA-DR Antigens
Clinical Protocols
Cytogenetics
Therapeutics
Monoclonal Antibodies
Guidelines
Drug Therapy

Keywords

  • Childhood ALL
  • Immunophenotyping
  • Monoclonal antibodies
  • Targeted therapies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Gudowius, S., Recker, K., Laws, H. J., Dirksen, U., Tröger, A., Wieczorek, U., ... Hanenberg, H. (2006). Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klinische Padiatrie, 218(6), 327-333. https://doi.org/10.1055/s-2006-942273

Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. / Gudowius, S.; Recker, K.; Laws, H. J.; Dirksen, U.; Tröger, A.; Wieczorek, U.; Furlan, S.; Göbel, U.; Hanenberg, Helmut.

In: Klinische Padiatrie, Vol. 218, No. 6, 11.2006, p. 327-333.

Research output: Contribution to journalArticle

Gudowius, S, Recker, K, Laws, HJ, Dirksen, U, Tröger, A, Wieczorek, U, Furlan, S, Göbel, U & Hanenberg, H 2006, 'Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL', Klinische Padiatrie, vol. 218, no. 6, pp. 327-333. https://doi.org/10.1055/s-2006-942273
Gudowius, S. ; Recker, K. ; Laws, H. J. ; Dirksen, U. ; Tröger, A. ; Wieczorek, U. ; Furlan, S. ; Göbel, U. ; Hanenberg, Helmut. / Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. In: Klinische Padiatrie. 2006 ; Vol. 218, No. 6. pp. 327-333.
@article{50d02d500ddb49b8b062b3db894059dd,
title = "Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL",
abstract = "Background: Contemporary risk adapted treatment protocols for childhood acute lymphoblastic leukemia (ALL) rely on accurate risk assessment strategies for disease reoccurrence by incorporating clinical parameters as well as immunological, molecular and cytogenetic features of the blasts at initial manifestation. Additional risk stratification is provided by analysis of the in vitro and in vivo response of the blasts towards standard chemotherapy. Despite adapted therapies, a number of children with good and bad prognostic factors still fail therapy. One approach to this problem might be to incorporate monoclonal antibodies (MoAbs) as additional modalities into the first or second line treatment. Patients and Methods: In order to identify target antigen structures, we analyzed the immunological expression profiles of blasts from 181 patients with B-cell precursor ALL treated at our institution in 11 years according to the CoALL-92/ 97/03 protocols. Blasts were classified according to the EGIL guidelines as 9 proB-, 110 common (c-) and 62 preB-ALL Results: >99 and 96{\%} of patients expressed CD19 and CD22 on >90{\%} of their blasts, respectively. HLA-DR on >95{\%} blasts was present in all patients. CD10 was expressed on all c-/preB-ALL and absent on proB-ALL cells. CD20 was expressed on 11-37{\%} of B-cell precursor ALL samples. CD34 positive blasts were found in 89, 83 and 68{\%} of patients with proB-, c- and preB-ALL, respectively. CD37 expression was detected in 0-18{\%} of patients.",
keywords = "Childhood ALL, Immunophenotyping, Monoclonal antibodies, Targeted therapies",
author = "S. Gudowius and K. Recker and Laws, {H. J.} and U. Dirksen and A. Tr{\"o}ger and U. Wieczorek and S. Furlan and U. G{\"o}bel and Helmut Hanenberg",
year = "2006",
month = "11",
doi = "10.1055/s-2006-942273",
language = "English (US)",
volume = "218",
pages = "327--333",
journal = "Klinische Padiatrie",
issn = "0300-8630",
publisher = "Georg Thieme Verlag",
number = "6",

}

TY - JOUR

T1 - Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL

AU - Gudowius, S.

AU - Recker, K.

AU - Laws, H. J.

AU - Dirksen, U.

AU - Tröger, A.

AU - Wieczorek, U.

AU - Furlan, S.

AU - Göbel, U.

AU - Hanenberg, Helmut

PY - 2006/11

Y1 - 2006/11

N2 - Background: Contemporary risk adapted treatment protocols for childhood acute lymphoblastic leukemia (ALL) rely on accurate risk assessment strategies for disease reoccurrence by incorporating clinical parameters as well as immunological, molecular and cytogenetic features of the blasts at initial manifestation. Additional risk stratification is provided by analysis of the in vitro and in vivo response of the blasts towards standard chemotherapy. Despite adapted therapies, a number of children with good and bad prognostic factors still fail therapy. One approach to this problem might be to incorporate monoclonal antibodies (MoAbs) as additional modalities into the first or second line treatment. Patients and Methods: In order to identify target antigen structures, we analyzed the immunological expression profiles of blasts from 181 patients with B-cell precursor ALL treated at our institution in 11 years according to the CoALL-92/ 97/03 protocols. Blasts were classified according to the EGIL guidelines as 9 proB-, 110 common (c-) and 62 preB-ALL Results: >99 and 96% of patients expressed CD19 and CD22 on >90% of their blasts, respectively. HLA-DR on >95% blasts was present in all patients. CD10 was expressed on all c-/preB-ALL and absent on proB-ALL cells. CD20 was expressed on 11-37% of B-cell precursor ALL samples. CD34 positive blasts were found in 89, 83 and 68% of patients with proB-, c- and preB-ALL, respectively. CD37 expression was detected in 0-18% of patients.

AB - Background: Contemporary risk adapted treatment protocols for childhood acute lymphoblastic leukemia (ALL) rely on accurate risk assessment strategies for disease reoccurrence by incorporating clinical parameters as well as immunological, molecular and cytogenetic features of the blasts at initial manifestation. Additional risk stratification is provided by analysis of the in vitro and in vivo response of the blasts towards standard chemotherapy. Despite adapted therapies, a number of children with good and bad prognostic factors still fail therapy. One approach to this problem might be to incorporate monoclonal antibodies (MoAbs) as additional modalities into the first or second line treatment. Patients and Methods: In order to identify target antigen structures, we analyzed the immunological expression profiles of blasts from 181 patients with B-cell precursor ALL treated at our institution in 11 years according to the CoALL-92/ 97/03 protocols. Blasts were classified according to the EGIL guidelines as 9 proB-, 110 common (c-) and 62 preB-ALL Results: >99 and 96% of patients expressed CD19 and CD22 on >90% of their blasts, respectively. HLA-DR on >95% blasts was present in all patients. CD10 was expressed on all c-/preB-ALL and absent on proB-ALL cells. CD20 was expressed on 11-37% of B-cell precursor ALL samples. CD34 positive blasts were found in 89, 83 and 68% of patients with proB-, c- and preB-ALL, respectively. CD37 expression was detected in 0-18% of patients.

KW - Childhood ALL

KW - Immunophenotyping

KW - Monoclonal antibodies

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=33845261567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845261567&partnerID=8YFLogxK

U2 - 10.1055/s-2006-942273

DO - 10.1055/s-2006-942273

M3 - Article

VL - 218

SP - 327

EP - 333

JO - Klinische Padiatrie

JF - Klinische Padiatrie

SN - 0300-8630

IS - 6

ER -